Bone News and Research

RSS

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.

11 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012

Mothers with vitamin D deficiency have babies with lower birth weight

Mothers' vitamin D levels at a gestation of 26 weeks or less were positively related to birth weight and head circumference, and, in the first trimester were negatively associated with risk of a baby being born small for gestational age, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

11 Dec 2012

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA.

10 Dec 2012

Erect radiographs reveal missed cervical spine instability

Erect radiographs are necessary to rule out unstable cervical spine injuries, UK researchers report.

10 Dec 2012

Natural product to combat menopause symptoms

Menopause is a time of great changes for most women, but information about this change of life is often sparse and contradictory. Options for symptom relief are limited. Natural products can be a healthier alternative and can provide symptom relief

10 Dec 2012

New study could help develop anti-inflammatory drugs with fewer side effects

10 Dec 2012

Amgen signs definitive agreement to acquire deCODE Genetics

Amgen and deCODE Genetics today announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics, a global leader in human genetics, headquartered in Reykjavik, Iceland.

10 Dec 2012

Simple technique based on principles of craniofacial surgery can maximize patient outcomes

As surgical teams gain experience with facial transplantation, a careful approach to planning based on the principles of craniofacial surgery can help to maximize patient outcomes in terms of facial form and function, according to an article in The Journal of Craniofacial Surgery.

10 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

Cervical disc replacement: an interview with Joe Ross, VP of U.S. Marketing at LDR

Cervical disc replacement is a surgical procedure that involves removing a damaged or degenerated cervical disc and replacing it with an artificial disc device.

10 Dec 2012

Vorinostat reduces risk of graft-vs.-host disease from bone marrow transplant treatments

A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Angiocidin reduces acute myeloid leukemia cells in vivo by almost two-thirds in pre-clinical studies

Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.

10 Dec 2012

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.

10 Dec 2012

Bone News and Research

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Mothers with vitamin D deficiency have babies with lower birth weight

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

Erect radiographs reveal missed cervical spine instability

Natural product to combat menopause symptoms

New study could help develop anti-inflammatory drugs with fewer side effects

Amgen signs definitive agreement to acquire deCODE Genetics

Simple technique based on principles of craniofacial surgery can maximize patient outcomes

New hope for leukemia patients

Cervical disc replacement: an interview with Joe Ross, VP of U.S. Marketing at LDR

Vorinostat reduces risk of graft-vs.-host disease from bone marrow transplant treatments

Ibrutinib may effectively combat chronic lymphocytic leukemia

Angiocidin reduces acute myeloid leukemia cells in vivo by almost two-thirds in pre-clinical studies

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News